Cantor Fitzgerald, L. P. Seres Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $1.04 Billion
- Q3 2024
A detailed history of Cantor Fitzgerald, L. P. transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 280,565 shares of MCRB stock, worth $154,310. This represents 0.03% of its overall portfolio holdings.
Number of Shares
280,565Holding current value
$154,310% of portfolio
0.03%Shares
2 transactions
Others Institutions Holding MCRB
# of Institutions
82Shares Held
40.5MCall Options Held
304KPut Options Held
471K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$12.7 Million3.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.06MShares$3.33 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.76MShares$969,1860.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.39MShares$763,7510.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.19MShares$656,0110.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $68.2M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...